1 completed, 1 terminated, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
Follow CABYC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning Alemtuzumab - Graft Versus Host Disease | Phase 2 | Terminated | CABYC | 34 | 2008-07-01 | 2015-02-04 |
| R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia Rituximab-CHOP-Alemtuzumab - Chronic Lymphocytic Leukaemia, Patients Resistant to a Purine Analogous | Phase 2 | Withdrawn | CABYC | 2007-07-01 | 2011-12-30 | |
| Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02) Y-90 Ibritumomab tiuxetan - Mantle Cell Lymphoma | Phase 2 | Completed | CABYC | 30 | 2006-01-01 | 2012-01-02 |
Graft vs Host Disease (1) · Leukemia, B-Cell (1) · Lymphoma, Mantle-Cell (1)
Alemtuzumab (1) · ibritumomab tiuxetan (1)
Spain (3)
Francesc Bosch, MD, PhD (1) · Rafael Duarte, MD, Ph.D (1) · Reyes Arranz, MD, PhD (1)
2005 (1)